Update on a Tethered Transapical Device for TMVR Vinay Badhwar, MD
|
|
- Calvin Jenkins
- 6 years ago
- Views:
Transcription
1 Update on a Tethered Transapical Device for TMVR Vinay Badhwar, MD Gordon F. Murray Professor and Chairman Department of Cardiovascular & Thoracic Surgery WVU Heart and Vascular Institute West Virginia University Morgantown, WV
2 Disclosures No Relevant Financial Disclosures Co-Chair Tendyne Global Steering Committee, operated by Abbott (uncompensated)
3 Transcatheter MVR Landscape Company Product MR Target Approach Regulatory Status Abbott Vascular Tendyne Primary/Secondary TA FIH CE Trial, US EFS Neovasc Tiara Primary/Secondary TA FIH CE Trial, US EFS Edwards Lifesciences CardiaQ Primary/Secondary TA, TS FIH CE Trial, US EFS Medtronic Twelve Secondary TA FIH OUS/US EFS Edwards Lifesciences Fortis Secondary TA FIH OUS EFS halted MValve Technologies Boston Scientific MValve Primary/Secondary TA FIH OUS EFS Cephea/Abbott Cephea Secondary TF Pre-Clinical In Development HeartWare/Valtech Cardiovalve Secondary TF Pre-Clinical In Development MitrAssist MitrAssist Primary/Secondary TA Pre-Clinical In Development HighLife HighLife MVR Secondary TA, TF Pre-Clinical In Development Emory University MitraCath Secondary TA Pre-Clinical In Development Micro Interventional EndoValve Secondary TF Pre-Clinical In Development NCSI, Inc. Navigate TMVR Secondary TA, TF Pre-Clinical In Development One Valve OneValve Primary/Secondary TS Pre-Clinical In Development J Thorac Cardiovasc Surg 2016;152:330-6
4 Tendyne Transapical, retrievable repositionable trileaflet porcine valve with an impermeable nitinol skirt Variable D-shaped self expanding outer frame, constant circular inner core Atrial component has large mm cuff Apical tether anchoring mechanism with secure locking pad
5 Tendyne Inclusion Criteria Severe MR of primary or secondary etiology NYHA class II, III or ambulatory IV Age >18yrs, able to provide informed consent Not suitable candidate for cardiac surgery as determined by the Heart team (including Cardiologist, Imager and Cardiac Surgeon)
6 Tendyne Exclusion Criteria Severe mitral annular or valvular calcification/stenosis, vegetation or mass Largest annular dimension <45mm LVEDD >70mm, LVEF<30% severe TR/RV dysfunction/pulmonary HTN Prior aortic or mitral valve surgery Small neo-lvot (echo, CT model, 3D printing)
7
8
9
10 Image courtesy of D. Muller, St Vincent s Hospital
11 Tendyne LP Valve Design Tendyne LP 2.0 valve Tendyne 1.0 valve Smaller sealing body height Smaller inner frame diameter
12 Tendyne Low Profile 2.0 Valve Introduced into CE Mark Study in mid-2016 and US EFS late-2016 Estimated to reduce screen failure for LVOTO by ~50% Tendyne LP valve (blue) Tendyne 1.0 valve (yellow) Tilted (biased) trajectory Orthogonal trajectory
13 Tendyne Early Results Global Feasibility Trial (n=30) JACC 2017;69:
14 Global Tendyne Experience Abbott NW West Virginia University EFS/CE Mark Study Site Name (n=18 sites) St. Vincent s Prince Charles Hospital Baylor Delray Medical Center Northshore Emory Henry Ford Hospital Pinnacle Health Cleveland Clinic MedStar Honor Health Oslo University Hospital San Donato Royal Brompton Flinders San Raffaele Total experience > 100 cases Longest follow-up 2.9 yrs US Pivotal Commencing 2018
15 Tendyne GFS (n=75) Age at Baseline Mean+SD years Range years Gender Male 50/75 (67%) Female 25/75 (33%) NYHA Functional Class II 26/74 (35%) III 45/74 (61%) IV 3/74 (4%) STS Score (range) (2-16 ) STS>8 27/75 (36%)
16 Tendyne GFS (n=75) Characteristics Primary (n=20) Secondary (n=55) Age Female gender 9/20 (45%) 16/55 (29%) NYHA III/IV 15/20 (75%) 33/54 (61%) STS PROM >8 7/20 (35%) 20/55 (36%) LVEF 52% 47% Pulmonary HT 58% 38% Atrial fibrillation 75% 60%
17 Tendyne GFS: 30-day Outcomes Protocol Defined Device Success at 30 Days Success 80% (60/75) Any Failure* 20% (15/75) Mortality 6.7% (5/75) Implant not Successful 4.0% (3/75) LVOT Obstruction 1.3% (1/75) Valve did not seat properly 1.3% (1/75) Patient became hemodynamically unstable, procedure 1.3% (1/75) not completed, unplanned circulatory support Any re-intervention 2.6% (2/75) Reposition Device- resolve PVL 1.3% (1/75) Bleeding with re-operation 1.3% (1/75) Device-related performance or Adverse Events* 5.3% (6/75) Mitral valve gradient > 6 mmhg 5.3% (4/75) Paravalvular Leak 1.3% (1/75) Device Malpositioning 1.3% (1/75) Device Thrombosis 1.3% (1/75) *Note: Multiple events in single patients - patient totals are not equal to individual event totals (rows do not sum as expected)
18 Tendyne Summary Fully retrievable, repositionable device Predictable, controlled deployment Well tolerated hemodynamically No procedural deaths or strokes Excellent valve performance and low mortality at 30 days Improvements in LV volume, NYHA class, QOL at 30 days CE Mark Study / Expanded Global Feasibility Study US Pivotal in 2018
19 A Contemporary TMVR Paradigm W eary of careful patient selection inclusive chest and apex A nchoring to leaflets and annulus T ranseosophageal Imaging and TMVR Thrombosis C omplexities of leaflets, subvalvular apparatus H OCM and navigating LV and papillary muscle architecture O utflow tract and potential obstruction of anterior leaflet U nderstanding true pathoanatomic mechanism T eam decision making including Imager, Surgeon, IC
20
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS, MD St Vincent s Hospital, Sydney On behalf of the Tendyne
More informationMy Choice For Percutaneous Mitral Valve Replacement. Jose Luis Navia, MD.
My Choice For Percutaneous Mitral Valve Replacement Jose Luis Navia, MD. Disclosure Edwards Lifescienses St. Jude Medical MAQUET NaviGate Consultant, Investigator Consultant, Investigator Consultant, Investigator
More informationUpdate on Transcatheter Mitral Valve Repair and Replacment
Update on Transcatheter Mitral Valve Repair and Replacment Vinod H. Thourani, MD Professor of Surgery Chair, Department of Cardiac Surgery Medstar Heart and Vascular Washington Hospital Center Georgetown
More informationTranscatheter Mitral Valve for fmr: The Era of Too Many Options
Transcatheter Mitral Valve for fmr: The Era of Too Many Options Isaac George, M.D. Surgical Director, Structural Heart & Valve Center Assistant Professor of Surgery Columbia University Medical Center Disclosure
More informationTranscatheter Mitral Valve Replacement How Close Are We?
Transcatheter Mitral Valve Replacement How Close Are We? Gregory Pavlides, MD, PhD, FACC, FESC Professor of Medicine Miscia Chair of Interventional Cardiology Director, Cardiac Catheterization Laboratories,
More informationTranscatheter Mitral Valve Interventions: Clinical Indications. Didier TCHETCHE, MD. Clinique Pasteur, Toulouse, France.
Transcatheter Mitral Valve Interventions: Clinical Indications Didier TCHETCHE, MD. Clinique Pasteur, Toulouse, France. Conflicts of interest: -Consultant for Medtronic -Consultant for Cephea Anatomy of
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA
William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA Mitral Valve Disease Today Mitral regurgitation is the most
More informationTranscatheter Mitral Valve Implantation: Techniques and Early Clinical Outcomes. Dr. T. Modine MD, PhD, MBA Heart team CHRU de Lille
Transcatheter Mitral Valve Implantation: Techniques and Early Clinical Outcomes Dr. T. Modine MD, PhD, MBA Heart team CHRU de Lille Speaker's name: Thomas Modine I have the following potential conflicts
More informationOutline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines
Advances in Percutaneous Mitral Valve Repair and Replacement Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando,
More informationGet Ready for Percutaneous Mitral Valve Approaches
Get Ready for Percutaneous Mitral Valve Approaches Paul A. Grayburn, MD Baylor Scott and White Healthcare System The Heart Hospital Baylor Plano and Baylor Heart and Vascular Hospital Dallas, TX HOPE Unmet
More informationSergio Berti Ospedale del Cuore Fondazione C.N.R. Reg Toscana Massa/Pisa
Sergio Berti Ospedale del Cuore Fondazione C.N.R. Reg Toscana Massa/Pisa Prevalence of Valvular Disease The Lancet, Vol. 368, Nkomo, V. T. et al., Burden of valvular heart diseases: a population-based
More informationCite this article as:
doi: 10.21037/acs.2018.10.01 Cite this article as: Beller JP, Rogers JH, Thourani VH, Ailawadi G. Early clinical results with the Tendyne transcatheter mitral valve replacement system. Ann Cardiothorac
More informationEmerging Mitral Technologies Where Are We Now? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH DALLAS, TX
Emerging Mitral Technologies Where Are We Now? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH DALLAS, TX Conflict of Interest Disclosure Abbott Vascular- Co PI COAPT Trial Medtronic- Executive Committee
More informationLivaNova Investor Day
LivaNova Investor Day TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) Paul Buckman General Manager, TMVR September 14, 2017 Safe Harbor Statement Certain statements in this presentation, other than purely
More informationTranscatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health
Transcatheter Mitral Innovations, Part II Michael Mack, M.D. Baylor Scott & White Health Conflict of Interest Disclosure Co-PI of the COAPT Trial of MitraClip sponsored by Abbott Vascular Uncompensated
More informationPercutaneous mitral valve repair/replacement. Jan Van der Heyden MD, PhD St.Antonius Hospital Nieuwegein
Percutaneous mitral valve repair/replacement Jan Van der Heyden MD, PhD St.Antonius Hospital Nieuwegein Mitral Valve anatomy Difference between AoV and MV Aortic Valve Mitral Valve Transcatheter Mitral
More informationNext Generation Therapies: Aortic, Mitral and Beyond
Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017 Next Generation Therapies:
More informationCite this article as:
doi: 10.21037/acs.2018.09.05 Cite this article as: Cheung A. Early experience of TIARA transcatheter mitral valve replacement system.. doi: 10.21037/acs.2018.09.05 This is a PDF file of an edited manuscript
More informationEarly Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study
Early Experience of Transcatheter Mitral Valve Replacement Results from the Paul Sorajja, MD for the Investigators Presenter Disclosure Information Within the past 12 months, I or my spouse/partner have
More informationSutureless Mitral and Tricuspid Clamp Valves
Sutureless Mitral and Tricuspid Clamp Valves Simple non-stent annular attachment Dr. Eric Berreklouw, MD PhD Daidalos Solutions B.V. Eindhoven/Son, The Netherlands Disclosures and acknowledgements Author
More informationMitral Programme Update
Direct Flow Medical Innovations in the Aortic and Mitral Programmes Mitral Programme Update Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy Potential conflicts
More informationMitral regurgitation (MR) is the most common
Percutaneous Mitral Valve Replacement An overview of the transcatheter valve replacement therapies for treating mitral regurgitation. BY ANDER REGUEIRO, MD, AND JOSEP RODÉS-CABAU, MD Mitral regurgitation
More informationSURGICAL AND TRANSCATHETER MITRAL VALVE REPLACEMENT VS. REPAIR: COMPETITION OR SYNERGY
SURGICAL AND TRANSCATHETER MITRAL VALVE REPLACEMENT VS. REPAIR: COMPETITION OR SYNERGY Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research
More information2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
More informationAlec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France
Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat
More informationSAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
More informationMITRAL (Mitral Implantation of TRAnscatheter valves)
MITRAL (Mitral Implantation of TRAnscatheter valves) 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationAPOLLO TMVR Trial Update: Case Presentation
APOLLO TMVR Trial Update: Case Presentation Anelechi Anyanwu, MD, MSc, FRCS-CTh Professor and Vice-Chairman Department of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Disclosure
More informationCritical role of multi-modality planning in Transcatheter Mitral Valve Replacement
Critical role of multi-modality planning in Transcatheter Mitral Valve Replacement Dee Dee Wang, MD, FACC, FASE, FSCCT Director Structural Heart Imaging Medical Director 3D Printing Henry Ford Innovations
More informationMITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification. Rheumatic Mitral Stenosis 76yo male
MITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification David S Rubenson MD FACC FASE Founding Director, Cardiac Non-Invasive Laboratory Scripps Clinic Medical Group number 1 Rheumatic Mitral Stenosis
More informationTREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC
TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC NATURAL HISTORY OF MITRAL REGURGITATION Abdallah El Sabbagh et al. JIMG 2018;11:628-643 TREATMENT OPTIONS SURGERY REPAIR REPLACEMENT PERCUTANEOUS INTERVENTIONS
More informationProgress In Transcatheter Aortic Valve Implantation
Progress In Transcatheter Aortic Valve Implantation Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia 4 th APCASH 8 th Sept 2013 Disclosure Statement
More informationTranscatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes
All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More informationDurability of Mitral Valve Surgery: Repair, Replacement or simply a clip? Christoph Huber Chirurgie Cardio Vasculaire HUG
Durability of Mitral Valve Surgery: Repair, Replacement or simply a clip? Christoph Huber Chirurgie Cardio Vasculaire HUG La chirurgie cardiaque innovatrice et durable Mitral valve disease Mitral regurgitation
More informationEarly Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study
Early Experience of Transcatheter Mitral Valve Replacement Results from the Paul Sorajja, MD for the Investigators Presenter Disclosure Information Within the past 12 months, I or my spouse/partner have
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia
Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationProfessor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical. The Houston Aortic Symposium February 23-25, 2017
James S. Gammie, MD Professor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical The Houston Aortic Symposium February 2-25, 2017 Disclosure Statement of Financial Interest Within
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More informationTranscatheter Mitral & Tricuspid Therapies. Bernard J. Zovighian Corporate Vice President
Transcatheter Mitral & Tricuspid Therapies Bernard J. Zovighian Corporate Vice President We Will Lead and Transform Treatment for Patients with Mitral and Tricuspid Diseases Mitral and Tricuspid Diseases
More informationCurrent Evidence in TAVI patients using ACURATE and LOTUS valves
Current Evidence in TAVI patients using ACURATE and LOTUS valves Giuseppe Tarantini, MD, PhD, FESC, Professor and Director of Interventional Cardiology University of Padua GISE President Potential conflicts
More informationTranscatheter Aortic Valve Replacement with Evolut-R
Transcatheter Aortic Valve Replacement with Evolut-R Department of Transcatheter Heart Valves and 2 nd Cardiothoracic Surgery Clinic K. Spargias, M.Chrissoheris, A.Halapas, I. Nikolaou, S.Pattakos Disclosures
More informationPercutaneous Valve in Native With and Without Mitral Valve Calcification: When To Go Hybrid
Percutaneous Valve in Native With and Without Mitral Valve Calcification: When To Go Hybrid Deborah Tabachnick, MD Cardiac Surgeon The Heart Hospital Baylor Plano Baylor Scott & White Health Disclosures
More informationTMVR Transcatheter Valve-in-Valve: Technical Considerations
TMVR Transcatheter Valve-in-Valve: Technical Considerations JOHN C. MESSENGER, MD, FACC, FSCAI PROFESSOR OF MEDICINE DIRECTOR, CARDIAC CATHETERIZATION LABS UNIVERSITY OF COLORADO SCHOOL OF MEDICINE Disclosures:
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationMulticentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system
Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Preliminary Results: Acute and 1-year Outcomes Ganesh Manoharan, MBBCh, MD, FRCP Consultant Cardiologist
More informationAn Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.
An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,
More informationPortico (St. Jude Medical Inc, St.
Review Article Portico Transcatheter Heart Valve Apostolos Tzikas 1,2, Michael Chrissoheris 2, Antonios Halapas 2, Konstantinos Spargias 2 1 Interbalkan European Medical Centre, Thessaloniki, 2 Hygeia
More informationDevelopment of a TMVR Device Challenge to Innovators
Development of a TMVR Device Challenge to Innovators Eberhard Grube MD, FACC, FSCAI, FAPSIC University Bonn, Heart Center, Bonn, Germany Stanford Universuty, School of Medicine, Palo Alto, CA Disclosure
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationPERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL
PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL DISCLOSURES I WILL BE DISCUSSING OFF-LABEL USAGE OF DEVICES RELATED TO TMVR OBJECTIVES
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationTAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research
More informationPercutaneous Therapy for Calcific Mitral Valve Disease
31 st Annual State of the Art Echocardiography San Diego, CA February 18, 2018 5:00 5:15 PM 15 min Percutaneous Therapy for Calcific Mitral Valve Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive
More informationPercutaneous Therapy for Mitral Regurgitation: Current and Future Options: Could we do better today?
Percutaneous Therapy for Mitral Regurgitation: Current and Future Options: Could we do better today? Peter S. Fail, MD, FACC, FACP, FSCAI Director of the Cardiac Catheterization Laboratories and Interventional
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationNeal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
More informationPercutaneous Mitral Valve Repair
Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip
More informationReally Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients?
Really Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients? David H. Adams, MD Cardiac Surgeon-in-Chief Mount Sinai Health System Marie Josée and Henry R. Kravis Professor and
More information30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators
30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve Didier Tchétché, MD On Behalf of the CENTERA Investigators Speaker's name: Didier Tchétché, MD I have the following potential
More informationSAPIEN 3 Sizing Considerations:
SAPIEN 3 Sizing Considerations: Oversizing, Undersizing, or Volume reduction? John Webb MD St Paul s Hospital University of British Columbia Vancouver Disclosure Statement of Financial Interest Within
More informationEduardo de Marchena, M.D., F.A.C.C., F.A.C.P., F.S.C.A.I. Professor of Medicine & Surgery Associate Dean for International Medicine University of
Catheter Based Treatment of Valvular Heart Disease In the Adult Sping 2016 Eduardo de Marchena, M.D., F.A.C.C., F.A.C.P., F.S.C.A.I. Professor of Medicine & Surgery Associate Dean for International Medicine
More informationConsideration for Surgical Valves and
Valve Choice: Consideration for Surgical Valves and Rings for Future Valve-in-Valve Kendra J. Grubb, M.D., M.H.A, F.A.C.C. Surgical Director, Structural Heart and Valve Center Division of Cardiothoracic
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationTAVI: Transapical Procedures
Cardiology Update Davos TAVI: Transapical Procedures Volkmar Falk, MD University Hospital Zürich TA-AVI: antegrade, simple, safe The front door approach! Transapical TAVI Technical advantages of TA approach
More informationTAVR in 2020: What is Next!!!!
TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures
More informationClinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients
Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients Susheel Kodali, MD on behalf of The PARTNER Trial Investigators
More information3D Printing & Echocardiography
ASE SOTA Feb 19, 2018 3D Printing & Echocardiography Stephen H. Little, MD John S. Dunn Chair in Cardiovascular Research and Education, Associate professor, Weill Cornell Medicine Disclosures Personal
More informationDISCLOSURE. Mitral ViV: why? Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? UW Medicine NONE.
Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? G. Burkhard Mackensen, MD, PhD, FASE Professor & Chief, Division of Cardiothoracic Anesthesia, Department of Anesthesiology
More informationSurgeon Involvement in Transcatheter Valve Therapy
Surgeon Involvement in Transcatheter Valve Therapy Prof. Hendrik Treede Mid-German Heartcenter University Hospital Halle (Saale) Once upon a time. classic interventional cardiology classic cardiac surgery
More informationTAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology
TAVR for Valve-In-Valve Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology Temple Hearth and Vascular Institute Disclosures: Consultant: Cardiac Assist TAVR for
More informationTAVI EN INSUFICIENCIA AORTICA
TAVI EN INSUFICIENCIA AORTICA Cesar Moris Profesor Cardiología Director Departamento del Corazón Hospital Universitario Central de Asturias Universidad de Oviedo OVIEDO -- ESPAÑA CONFLICTO DE INTERESES
More informationOutline. EuroScore II. Society of Thoracic Surgeons Score. EuroScore II
SURGICAL RISK IN VALVULAR HEART DISEASE: WHAT 2D AND 3D ECHO CAN TELL YOU AND WHAT THEY CAN'T Ernesto E Salcedo, MD Professor of Medicine University of Colorado School of Medicine Director of Echocardiography
More informationMitral Regurgitation
Mitral Regurgitation Focus on Percutaneous Repair Steven J. Yakubov, MD FACC FSCAI System Chief, Structural Heart Diseaese, OhioHealth John H. McConnell Chair of Advanced Structural Heart Disease Medical
More informationNovel mitral valve technologies transcatheter mitral valve implantation: a systematic review
Systematic Review Novel mitral valve technologies transcatheter mitral valve implantation: a systematic review Campbell D. Flynn 1,2, Ashley R. Wilson-Smith 2,3, Tristan D. Yan 2,3,4 1 Department of Cardiothoracic
More informationAustralia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes
Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes A/ Professor Darren Walters On behalf of the ANZ Source Investigators Director of Cardiology Brisbane, Australia ANZ
More informationTAVR SPRING 2017 The evolution of TAVR
TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More information30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
More informationHow Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, 2016 11:00 11:25 PM 25 min 1 M U H A M E D S A R I Ć, M D, P H D
More informationThe Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline
More informationAppropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK
Appropriate Use of TAVR - now and in the future A Surgeon s Perspective Neil Moat Royal Brompton Hospital, London, UK Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner
More informationProcedural Guidance of TAVR: How to Assure it Goes Right and What to Do If It Doesn t
Procedural Guidance of TAVR: How to Assure it Goes Right and What to Do If It Doesn t James D. Thomas, M.D., F.A.C.C. Department of Cardiovascular Medicine Heart and Vascular Institute Cleveland Clinic
More informationCardioband: una chance per l insufficienza mitralica funzionale
HEARTLINE Genova 10-11 novembre 2017 Cardioband: una chance per l insufficienza mitralica funzionale Sergio Berti Ospedale del Cuore Fondazione C.N.R. Reg Toscana Massa/Pisa Reduction of Septo Lateral
More informationFederico M Asch MD, FASE MedStar Heart and Vascular Institute Georgetown University Washington, DC
TAVR: When Things go Wrong Federico M Asch MD, FASE MedStar Heart and Vascular Institute Georgetown University Washington, DC Disclosures Academic Echo Core Lab Abbott / St Jude Medical Edwards Medtronic
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationComplexities of transcatheter mitral valve replacement (TMVR) and why it is not transcatheter aortic valve replacement (TAVR)
Keynote Lecture Series Complexities of transcatheter mitral valve replacement (TMVR) and why it is not transcatheter aortic valve replacement (TAVR) Moritz C. Wyler von Ballmoos 1,2, Ankur Kalra 3, Michael
More informationMitral Valve Disease. James Hermiller, MD, FACC, FSCAI St Vincent Heart Center Indianapolis, IN
Mitral Valve Disease James Hermiller, MD, FACC, FSCAI St Vincent Heart Center Indianapolis, IN Disclosures Affiliation/Financial Relationship Consulting Fees/Honoraria Speaker Bureau Company Abbott, BSC,
More informationAortic Stenosis Background and Breakthroughs in Treatment: TAVR Update
Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder
More informationCoreValve Evolut R Technology review and Clinical Results. Paul TL Chiam
CoreValve Evolut R Technology review and Clinical Results Paul TL Chiam MBBS (S pore), MMed, MRCP (UK), FAMS FRCP (Edin), FESC (EU), FACC (USA), FSCAI (USA) Cardiologist Mount Elizabeth Hospital Singapore
More informationA new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
More informationNouvelles indications/ Nouvelles valves
Nouvelles indications/ Nouvelles valves Sadra Lotus Valve system Boston Scientific A. Tirouvanziam Institut Thorax Nantes SH-31314-AC Sept 2012 Slide 1 of 53 SH-31314-AC Sept 2012 Slide 2 of 53 Building
More informationEdwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?
Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Update from PARTNER EU and SOURCE Registries T. Lefèvre Disclosure Statement Cardiologist Interventional cardiologist 1 st PABV in
More informationPrognostic Impact of FMR
Secondary Mitral Valve Regurgitation in Heart Failure, Age 60 Years From Medical Therapy to Surgical Repair to Transcatheter Intervention The Interventionalist s View Samin K Sharma, MD, FACC, FSCAI Director
More informationThe FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation
The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve
More information